Overview

Selenium and Selenoproteins in Cancer, Volume 136, the latest release in the Advances in Cancer Research series, provides invaluable information on the fast-moving field of cancer research. This updated volume includes chapters on The epidemiology of selenium and human cancer, Selenium, epigenetics and cancer, Selenium status and cancer risk, Nutritional aspects of selenium and breast cancer risk: focus on cellular and molecular mechanisms, Selenoproteins in tumorigenesis and cancer progression, Selenoproteins and metastasis, The tumor microenvironment and inflammatory factors, and Selenium-dependent glutathione peroxidases during tumor development. This new release in the series presents original reviews on research regarding the prevention and treatment of cancer with selenium.

Full Product Details

Author:   Francesco Galli (Clinical Biochemistry and Human Nutrition, Department of Pharmaceutical Sciences, University of Perugia) ,  Kenneth D. Tew (Professor and Chairman, Department of Cell and Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA) ,  Kenneth D. Tew (Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA) ,  Kenneth D. Tew (Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA)
Publisher:   Elsevier Science Publishing Co Inc
Imprint:   Academic Press Inc
Weight:   0.630kg
ISBN:  

9780128120163

ISBN 10:   0128120169
Pages:   316
Publication Date:   19 October 2017
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

1. The Epidemiology of Selenium and Human Cancer Marco Vinceti, Tommaso Filippini, Silvia Cilloni, and Catherine M. Crespi 2. Selenoproteins in Tumorigenesis and Cancer Progression Sarah P. Short and Christopher S. Williams 3. Selenoproteins and Metastasis Michael P. Marciel and Peter R. Hoffmann 4. Selenium-Dependent Glutathione Peroxidases During Tumor Development Anna P. Kipp 5. Targeting the Selenoprotein Thioredoxin Reductase 1 for Anticancer Therapy Elias S.J. Arnér 6. The Regulation of Pathways of Inflammation and Resolution in Immune Cells and Cancer Stem Cells by Selenium Bastihalli T. Diwakar, Arvind M. Korwar, Robert F. Paulson, and K. Sandeep Prabhu 7. Selenium and Breast Cancer Risk: Focus on Cellular and Molecular Mechanisms Camile C. Fontelles and Thomas P. Ong 8. Selenium and Epigenetics in Cancer: Focus on DNA Methylation Ewa Jablonska and Edyta Reszka 9. Selenium and Cancer Stem Cells Giuseppe Murdolo, Desirée Bartolini, Cristina Tortoioli, Marta Piroddi, Pierangelo Torquato, and Francesco Galli 10. elenocompounds in Cancer Therapy: An Overview Desirée Bartolini, Luca Sancineto, Andreza Fabro de Bem, Kenneth D. Tew, Claudio Santi, Rafael Radi, Pierangelo Toquato, and Francesco Galli

Reviews

Author Information

As the group leader and head of the research unit in the Department of Internal Medicine since 2013 and currently Dept of Pharmaceutical Sciences at University of Perugia, Francesco Galli's research is focussed on biochemistry, cellular biology and signaling, pharmacology/toxicology, and nutrition. Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USAThe Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions